Connection

Co-Authors

This is a "connection" page, showing publications co-authored by HUI YANG and YUE WEI.
Connection Strength

1.116
  1. Overexpression of miR-125a in myelodysplastic syndrome CD34+ cells modulates NF-?B activation and enhances erythroid differentiation arrest. PLoS One. 2014; 9(4):e93404.
    View in: PubMed
    Score: 0.118
  2. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia. 2014 Jun; 28(6):1280-8.
    View in: PubMed
    Score: 0.115
  3. Oncogenic functions of the transcription factor Nrf2. Free Radic Biol Med. 2013 Dec; 65:750-764.
    View in: PubMed
    Score: 0.112
  4. Toll-like receptor alterations in myelodysplastic syndrome. Leukemia. 2013 Sep; 27(9):1832-40.
    View in: PubMed
    Score: 0.112
  5. Global H3K4me3 genome mapping reveals alterations of innate immunity signaling and overexpression of JMJD3 in human myelodysplastic syndrome CD34+ cells. Leukemia. 2013 Nov; 27(11):2177-86.
    View in: PubMed
    Score: 0.110
  6. Levels of miR-29b do not predict for response in patients with acute myelogenous leukemia treated with the combination of 5-azacytidine, valproic acid, and ATRA. Am J Hematol. 2011 Feb; 86(2):237-8.
    View in: PubMed
    Score: 0.095
  7. The combination of a histone deacetylase inhibitor with the BH3-mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy. Autophagy. 2010 Oct; 6(7):976-8.
    View in: PubMed
    Score: 0.093
  8. The combination of a histone deacetylase inhibitor with the Bcl-2 homology domain-3 mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy. Clin Cancer Res. 2010 Aug 01; 16(15):3923-32.
    View in: PubMed
    Score: 0.091
  9. Telomere dysfunction drives aberrant hematopoietic differentiation and myelodysplastic syndrome. Cancer Cell. 2015 May 11; 27(5):644-57.
    View in: PubMed
    Score: 0.032
  10. RUNX3 promoter hypermethylation is frequent in leukaemia cell lines and associated with acute myeloid leukaemia inv(16) subtype. Br J Haematol. 2015 May; 169(3):344-51.
    View in: PubMed
    Score: 0.031
  11. Overexpression of the toll-like receptor (TLR) signaling adaptor MYD88, but lack of genetic mutation, in myelodysplastic syndromes. PLoS One. 2013; 8(8):e71120.
    View in: PubMed
    Score: 0.028
  12. Impact of aberrant DNA methylation patterns including CYP1B1 methylation in adolescents and young adults with acute lymphocytic leukemia. Am J Hematol. 2013 Sep; 88(9):784-9.
    View in: PubMed
    Score: 0.028
  13. Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML. Leukemia. 2013 Oct; 27(10):2081-3.
    View in: PubMed
    Score: 0.028
  14. Low frequency of H3.3 mutations and upregulated DAXX expression in MDS. Blood. 2013 May 09; 121(19):4009-11.
    View in: PubMed
    Score: 0.028
  15. Epigenetic inactivation of Notch-Hes pathway in human B-cell acute lymphoblastic leukemia. PLoS One. 2013; 8(4):e61807.
    View in: PubMed
    Score: 0.028
  16. Genome-wide DNA methylation profiling of chronic lymphocytic leukemia allows identification of epigenetically repressed molecular pathways with clinical impact. Epigenetics. 2010 Aug 16; 5(6):499-508.
    View in: PubMed
    Score: 0.023
  17. Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound ?-phenylethyl isothiocyanate. Blood. 2010 Oct 14; 116(15):2732-41.
    View in: PubMed
    Score: 0.023
  18. Genome-wide identification of aberrantly methylated promoter associated CpG islands in acute lymphocytic leukemia. Leukemia. 2008 Aug; 22(8):1529-38.
    View in: PubMed
    Score: 0.020
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.